Waverley Expands UK Cancer Portfolio
Marketing Authorizations Obtained For Erlotinib Tablets
Having made its entry into the UK oncology generics market late last year with capecitabine and temozolomide, Canada’s Waverley Pharma now has clearance to add erlotinib tablets to its portfolio.
You may also be interested in...
Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.
The latest generic, biosimilar and value-added drug development news and highlights from across the globe.
Canada’s Waverley Pharma has acquired two UK oncology generics, capecitabine and temozolomide, from Reliance Life Sciences. “The products were developed by Reliance Life Sciences and the binding contracts with the UK National Health Service (NHS) for the supply of these products are being transferred to Waverley Pharma,” the firm noted.